ctDNA Testing After Surgery Can Be Used To Predict RFS, OS In Patients With NSCLC, Research Indicates

Cancer Therapy Advisor (7/2, Schneider) reports, “Circulating tumor DNA (ctDNA) testing after surgery can be used to predict relapse-free survival (RFS) and overall survival (OS) in patients with non-small cell lung cancer (NSCLC), according to findings from a systematic review and meta-analysis.” Investigators “analyzed 13 studies involving 1283 patients with stage I-IV NSCLC.” The data indicated that “compared to patients who were ctDNA negative after surgery, those who were ctDNA positive had worse RFS...and OS...and this was true regardless of where they were treated, their disease stage, or the duration of follow-up.” The findings were published in Clinical Oncology.